Journal
JOURNAL OF CLINICAL LABORATORY ANALYSIS
Volume 37, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/jcla.24824
Keywords
biomarker; immune checkpoint blocker; immune infiltrates; LIPG; lung adenocarcinoma
Categories
Ask authors/readers for more resources
This study found that the expression of endothelial lipase gene (LIPG) is higher in lung adenocarcinoma (LUAD) and is associated with prognosis, lipid metabolism, and immune infiltration.
BackgroundAlthough many biomarkers for lung adenocarcinoma (LUAD) have been identified, their specificity and sensitivity remain unsatisfactory. Endothelial lipase gene (LIPG) plays an important role in a variety of cancers, but its role in lung adenocarcinoma remains unclear. MethodsTCGA, GEO, K-M plotter, CIBERSORT, GSEA, HPA, and GDSC were used to analyze LIPG in LUAD. Data analysis was mainly achieved by R 4.0.3. ResultsThe expression of LIPG in LUAD tissues was higher than that in adjacent normal tissues, especially in women, patients aged >65 years, and those with lymph node metastasis. High expression predicted a poor prognosis. The results of enrichment analysis suggest that LIPG may exert profound effects on the development of LUAD through multiple stages of lipid metabolism and immune system regulation. In addition, LIPG expression was significantly correlated with the expression levels of multiple immune checkpoint genes and the abundance of multiple immune infiltrates, including the activated memory CD4 T cell, M1 macrophage, neutrophil, plasma cells, and T follicular helper (Tfh) cells in the LUAD microenvironment content. At the same time, patients with high LIPG expression respond well to a variety of antitumor drugs and have a low rate of drug resistance. ConclusionsLIPG is a prognostic marker and is associated with lipid metabolism and immune infiltration in LUAD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available